Status:
COMPLETED
Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study
Lead Sponsor:
National Cancer Institute (NCI)
Collaborating Sponsors:
Finnish Institute for Health and Welfare
Conditions:
Stroke
Diabetes Mellitus
Eligibility:
MALE
50-69 years
Brief Summary
The project is a passive follow-up of the Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study cohort. Originally, this was a large, randomized, double-blind, placebo-controlled, 2x2 factori...
Detailed Description
The ATBC study was a randomized, double-blind, placebo-controlled, primary prevention trial to determine whether daily supplementation with a-tocopherol, beta-carotene, or both would reduce the incide...
Eligibility Criteria
Inclusion
- INCLUSION CRITERIA:
- Current smokers (five or more cigarettes per day at study entry) from Southwestern Finland.
- EXCLUSION CRITERIA:
- Females
- Proven malignancy (except nonmelanoma skin cancer or cancer in situ)
- Severe angina pectoris
- Chronic renal insufficiency
- Cirrhosis of the liver
- Chronic alcoholism
- Anticoagulant therapy
- Use of supplements containing vitamin E greater than 20 mg/day, or vitaming A greater than 20,000 IU/day, or beta-carotene greater than 6 mg/day
Exclusion
Key Trial Info
Start Date :
March 3 1995
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 4 2020
Estimated Enrollment :
29133 Patients enrolled
Trial Details
Trial ID
NCT00342992
Start Date
March 3 1995
End Date
September 4 2020
Last Update
September 9 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Institute of Health and Welfare, Helsinki, Finland
Helsinki, Finland